Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeuroVax in Secondary Progressive Multiple Sclerosis
NCT02057159Phase 3Unknown
- Sponsor
- Immune Response BioPharma, Inc.
- Start
- Mar 2020
- Primary completion
- Mar 2023
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of IR208 in secondary-progressive multiple sclerosis (SPMS), sponsored by Immune Response BioPharma, Inc.. Status: unknown.
02
Drugs
IR208
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT02057159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057159.